Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Pharmacology, Toxicology and Pharmaceutical Science
5
2%
Other
13
6%
Unknown
70
32%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 35. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2026.
All research outputs
#1,466,858
of 34,457,357 outputs
Outputs from Annals of the Rheumatic Diseases
#866
of 10,607 outputs
Outputs of similar age
#6,881
of 212,415 outputs
Outputs of similar age from Annals of the Rheumatic Diseases
#9
of 177 outputs
Altmetric has tracked 34,457,357 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,607 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.7. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,415 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 177 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.
